Found 43 clinical trials
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and strategy stratification are lacking. In this setting, a simple biological scoring system have recently been proposed, including LDH and CD138 binary status seric values, identifying one third of patients with worst prognostic. Intensified-chemotherapy strategies, combining 5-fluorouracile, Oxaliplatin, …
- 6 views
- 03 Aug, 2021
- 13 locations
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.
- 0 views
- 08 Mar, 2021
- 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients
A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)
- 37 views
- 06 Sep, 2021
- 37 locations
Proof of Concept Study of ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
The study will evaluate the efficacy and safety of the oral Factor D (FD) inhibitor ALXN2050 (ACH-0145228) monotherapy in patients with PNH that are treatment nave, or patients currently treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, …
- 2 views
- 31 May, 2021
- 9 locations
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases
Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been defined, and no consensus exist on criteria for resectability. In this study colorectal cancer patients with initially unresectable liver-only metastases, as prospectively …
- 177 views
- 23 Sep, 2021
- 64 locations
Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions. The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement …
- 83 views
- 21 Jan, 2021
- 1 location
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).
- 6 views
- 08 Nov, 2020
- 1 location
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
This is a pilot study evaluating the feasibility of using adaptive intermittent dosing of vemurafenib and cobimetinib in BRAF mutant patients with elevated baseline lactate dehydrogenase (LDH
- 9 views
- 19 Sep, 2021
- 1 location
Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
-risk cohorts including symptomatic brain metastases or liver metastases with elevated lactate dehydrogenase (LDH) or bulky systemic disease burden.
- 0 views
- 22 Jul, 2021
- 1 location
Effects of Phosphatidic Acid on Strength and Hypertrophy
, body composition, muscle cross-sectional area and food consumption. Samples of venous blood will also be collected to determine the concentration of creatine kinase (CK), lactate dehydrogenase (LDH
- 0 views
- 25 Jan, 2021
- 1 location